Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-064: ABBV-400 versus LONSURF + bevacizumab in c-Met-high refractory metastatic colorectal cancer
CTR20253836Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telisotuzumab adizutecan in colorectal cancer (CRC), sponsored by AbbVie Inc.. Started Oct 2025; status: terminated.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20253836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253836.